New pill challenges standard care for Tough-to-Treat blood cancers

NCT ID NCT06561048

Summary

This study is testing an experimental oral drug called soquelitinib against standard chemotherapy options for adults with specific aggressive T-cell lymphomas that have returned or not responded to prior treatment. About 150 participants will be randomly assigned to receive either the new pill or a standard single-agent chemotherapy chosen by their doctor. The main goal is to see if soquelitinib can keep the cancer from growing longer than the standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • North Carolina Cancer Hospital

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

    Contact

    Contact Email: •••••@•••••

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92697, United States

    Contact Email: •••••@•••••

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Maryland Medical Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Washington Fred Hutch Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Email: •••••@•••••

    Contact

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.